Impact Factor 4.137 | CiteScore 4.28
More on impact ›
The advent of novel surgical approaches and targeted personalized approaches for treatment for renal, prostate and bladder tumors have made a significant impact on patient outcomes, and refined the treatment paradigms for these cancers. Preclinical studies, molecular characterization of these tumors, and translational studies have and will continue to provide a major impetus for these developments.
Multispecialty clinical and research groups in Genitourinary (GU) Oncology have focused their clinical and basic research on questions related to the biology and therapy for malignancies arising in the kidney, prostate and bladder, however, communication of the results and research findings remains slow and at times a difficult process. Our ultimate goal is to provide a mechanism of communication between clinicians and researchers that will stimulate and promote a continuation of the multimodal strategies characteristic of the genitourinary oncology field.
This section welcomes Original Research and Reviews related to both clinical and basic research findings in the various GU malignancies on the following topics:
1) genetic characterization
2) relevant preclinical models
3) characterization of biologic pathways associated with tumor progression and growth
4) translational studies
5) development of novel therapeutic approaches
6) epidemiologic studies
7) clinical studies of novel and established therapeutic strategies
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Genitourinary Oncology welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Genitourinary Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Genitourinary Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org